Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Yes, you can cancel your order at any time before it has been shipped
The body regulated itself
Journal of Orthopaedic Translation, 32, 121129
SPL UNCLASSIFIED SECTION Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea, or SGLT-2 inhibitor) SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type 2 diabetes mellitus with increased cardiovascular risk to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin glargine 100 units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%)
Weight loss results were observed across all active dose groups in a dose-dependent pattern
By month three, weight loss often becomes more noticeable
US$ 27.41
US$ 24.53
US$ 24.98
US$ 24.94
US$ 25.50
US$ 24.64
